SCHEMBL21604599

SCHEMBL21604599

Cn1cc2cnc(Cl)cc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
NSD2 O96028 1/20 0.46
MAOA P21397 2/20 0.34
MAOB P27338 2/20 0.34
KDR P35968 2/20 0.33
KIT P10721 1/20 0.33
PDGFRA P16234 1/20 0.33
ADCY10 Q96PN6 5/20 0.33
FGFR3 P22607 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
PDE4D Q08499 1/20 0.32
HRH4 Q9H3N8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
NPC1 O15118 1/20 0.31
TP53 P04637 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22323295 0.85 KDM4E (0.42) KDM4EMAPTALDH1A1NSD2MAOA
SCHEMBL15980356 0.78 MAPT (0.47) KDM4EMAPTALDH1A1NSD2KDR
SCHEMBL27390060 0.77 MAPT (0.46) KDM4EMAPTALDH1A1NSD2KDR
SCHEMBL30162111 0.77 ADORA2A (0.37) ALDH1A1ADORA2AADORA1
SCHEMBL24989427 0.74 MAPT (0.43) KDM4EMAPTALDH1A1NSD2
SCHEMBL26109370 0.74 IRAK4 (0.37)
SCHEMBL21730118 0.73 MAPT (0.42) KDM4EMAPTALDH1A1NSD2KDR
SCHEMBL29268077 0.73 MAPT (0.42) KDM4EMAPTALDH1A1NSD2
SCHEMBL29268130 0.73 MAPT (0.42) KDM4EMAPTALDH1A1NSD2PDE4D
SCHEMBL31691547 0.72 NPC1 (0.50) MAPTALDH1A1ADORA2AADORA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210115040-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-04-22 US disclosed
WO-2019243528-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115040-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN KDM4E 1495/4885MAPT 7/4885ALDH1A1 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.